Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer.

Conteduca V, Castro E, Wetterskog D, Scarpi E, Jayaram A, Romero-Laorden N, Olmos D, Gurioli G, Lolli C, Sáez MI, Puente J, Schepisi G, Salvi S, Wingate A, Medina A, Querol-Niñerola R, Marin-Aguilera M, Arranz JA, Fornarini G, Basso U, Mellado B, Gonzalez-Billalabeitia E, Attard G, De Giorgi U.

Eur J Cancer. 2019 Jun 11;116:158-168. doi: 10.1016/j.ejca.2019.05.007. [Epub ahead of print]

PMID:
31200322
2.

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.

Conteduca V, Jayaram A, Romero-Laorden N, Wetterskog D, Salvi S, Gurioli G, Scarpi E, Castro E, Marin-Aguilera M, Lolli C, Schepisi G, Maugeri A, Wingate A, Farolfi A, Casadio V, Medina A, Puente J, Vidal MJM, Morales-Barrera R, Villa-Guzmán JC, Hernando S, Rodriguez-Vida A, González-Del-Alba A, Mellado B, Gonzalez-Billalabeitia E, Olmos D, Attard G, De Giorgi U.

Eur Urol. 2019 Mar;75(3):368-373. doi: 10.1016/j.eururo.2018.09.049. Epub 2018 Oct 26.

3.

Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test.

González-Billalabeitia E, Conteduca V, Wetterskog D, Jayaram A, Attard G.

Prostate Cancer Prostatic Dis. 2019 May;22(2):195-205. doi: 10.1038/s41391-018-0098-x. Epub 2018 Nov 9. Review.

4.

Plasma androgen receptor and serum chromogranin A in advanced prostate cancer.

Conteduca V, Scarpi E, Salvi S, Casadio V, Lolli C, Gurioli G, Schepisi G, Wetterskog D, Farolfi A, Menna C, De Lisi D, Burgio SL, Beltran H, Attard G, De Giorgi U.

Sci Rep. 2018 Oct 18;8(1):15442. doi: 10.1038/s41598-018-33774-4.

5.

Plasma DNA and Metastatic Castration-Resistant Prostate Cancer: The Odyssey to a Clinical Biomarker Test.

Jayaram A, Wetterskog D, Attard G.

Cancer Discov. 2018 Apr;8(4):392-394. doi: 10.1158/2159-8290.CD-18-0124.

6.

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.

Conteduca V, Wetterskog D, Sharabiani MTA, Grande E, Fernandez-Perez MP, Jayaram A, Salvi S, Castellano D, Romanel A, Lolli C, Casadio V, Gurioli G, Amadori D, Font A, Vazquez-Estevez S, González Del Alba A, Mellado B, Fernandez-Calvo O, Méndez-Vidal MJ, Climent MA, Duran I, Gallardo E, Rodriguez A, Santander C, Sáez MI, Puente J, Gasi Tandefelt D, Wingate A, Dearnaley D; PREMIERE Collaborators; Spanish Oncology Genitourinary Group, Demichelis F, De Giorgi U, Gonzalez-Billalabeitia E, Attard G.

Ann Oncol. 2017 Jul 1;28(7):1508-1516. doi: 10.1093/annonc/mdx155.

7.

Plasma AR and abiraterone-resistant prostate cancer.

Romanel A, Gasi Tandefelt D, Conteduca V, Jayaram A, Casiraghi N, Wetterskog D, Salvi S, Amadori D, Zafeiriou Z, Rescigno P, Bianchini D, Gurioli G, Casadio V, Carreira S, Goodall J, Wingate A, Ferraldeschi R, Tunariu N, Flohr P, De Giorgi U, de Bono JS, Demichelis F, Attard G.

Sci Transl Med. 2015 Nov 4;7(312):312re10. doi: 10.1126/scitranslmed.aac9511.

8.

LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling.

Chang J, Nicolau MM, Cox TR, Wetterskog D, Martens JW, Barker HE, Erler JT.

Breast Cancer Res. 2013;15(4):R67.

9.

Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers.

Wetterskog D, Shiu KK, Chong I, Meijer T, Mackay A, Lambros M, Cunningham D, Reis-Filho JS, Lord CJ, Ashworth A.

Oncogene. 2014 Feb 20;33(8):966-76. doi: 10.1038/onc.2013.41. Epub 2013 Mar 11.

PMID:
23474757
10.

Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutations.

Wetterskog D, Wilkerson PM, Rodrigues DN, Lambros MB, Fritchie K, Andersson MK, Natrajan R, Gauthier A, Di Palma S, Shousha S, Gatalica Z, Töpfer C, Vukovic V, A'Hern R, Weigelt B, Vincent-Salomon A, Stenman G, Rubin BP, Reis-Filho JS.

Histopathology. 2013 Mar;62(4):543-50. doi: 10.1111/his.12050. Epub 2013 Feb 12.

11.

Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies.

Shiu KK, Wetterskog D, Mackay A, Natrajan R, Lambros M, Sims D, Bajrami I, Brough R, Frankum J, Sharpe R, Marchio C, Horlings H, Reyal F, van der Vijver M, Turner N, Reis-Filho JS, Lord CJ, Ashworth A.

Oncogene. 2014 Jan 30;33(5):619-31. doi: 10.1038/onc.2012.625. Epub 2013 Jan 21.

12.

Functional characterization of the 19q12 amplicon in grade III breast cancers.

Natrajan R, Mackay A, Wilkerson PM, Lambros MB, Wetterskog D, Arnedos M, Shiu KK, Geyer FC, Langerød A, Kreike B, Reyal F, Horlings HM, van de Vijver MJ, Palacios J, Weigelt B, Reis-Filho JS.

Breast Cancer Res. 2012 Mar 20;14(2):R53.

13.

Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers.

Wetterskog D, Lopez-Garcia MA, Lambros MB, A'Hern R, Geyer FC, Milanezi F, Cabral MC, Natrajan R, Gauthier A, Shiu KK, Orr N, Shousha S, Gatalica Z, Mackay A, Palacios J, Reis-Filho JS, Weigelt B.

J Pathol. 2012 Jan;226(1):84-96. doi: 10.1002/path.2974. Epub 2011 Oct 20.

PMID:
22015727
14.

Functional viability profiles of breast cancer.

Brough R, Frankum JR, Sims D, Mackay A, Mendes-Pereira AM, Bajrami I, Costa-Cabral S, Rafiq R, Ahmad AS, Cerone MA, Natrajan R, Sharpe R, Shiu KK, Wetterskog D, Dedes KJ, Lambros MB, Rawjee T, Linardopoulos S, Reis-Filho JS, Turner NC, Lord CJ, Ashworth A.

Cancer Discov. 2011 Aug;1(3):260-73. doi: 10.1158/2159-8290.CD-11-0107. Epub 2011 Aug 2.

15.

Functional characterization of EMSY gene amplification in human cancers.

Wilkerson PM, Dedes KJ, Wetterskog D, Mackay A, Lambros MB, Mansour M, Frankum J, Lord CJ, Natrajan R, Ashworth A, Reis-Filho JS.

J Pathol. 2011 Sep;225(1):29-42. doi: 10.1002/path.2944. Epub 2011 Jul 7.

PMID:
21735447
16.

Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.

Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS.

Cell Cycle. 2011 Apr 15;10(8):1192-9. Epub 2011 Apr 15.

17.

Emerging therapeutic targets in endometrial cancer.

Dedes KJ, Wetterskog D, Ashworth A, Kaye SB, Reis-Filho JS.

Nat Rev Clin Oncol. 2011 May;8(5):261-71. doi: 10.1038/nrclinonc.2010.216. Epub 2011 Jan 11. Review.

PMID:
21221135
18.

PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.

Dedes KJ, Wetterskog D, Mendes-Pereira AM, Natrajan R, Lambros MB, Geyer FC, Vatcheva R, Savage K, Mackay A, Lord CJ, Ashworth A, Reis-Filho JS.

Sci Transl Med. 2010 Oct 13;2(53):53ra75. doi: 10.1126/scitranslmed.3001538.

19.

Cortactin gene amplification and expression in breast cancer: a chromogenic in situ hybridisation and immunohistochemical study.

Dedes KJ, Lopez-Garcia MA, Geyer FC, Lambros MB, Savage K, Vatcheva R, Wilkerson P, Wetterskog D, Lacroix-Triki M, Natrajan R, Reis-Filho JS.

Breast Cancer Res Treat. 2010 Dec;124(3):653-66. doi: 10.1007/s10549-010-0816-0. Epub 2010 Mar 6.

PMID:
20213079
20.

Dysregulation of platelet-derived growth factor beta-receptor expression by DeltaNp73 in neuroblastoma.

Wetterskog D, Moshiri A, Ozaki T, Uramoto H, Nakagawara A, Funa K.

Mol Cancer Res. 2009 Dec;7(12):2031-9. doi: 10.1158/1541-7786.MCR-08-0501. Epub 2009 Dec 1.

21.

Kinetics of repression by modified p53 on the PDGF beta-receptor promoter.

Yang W, Wetterskog D, Matsumoto Y, Funa K.

Int J Cancer. 2008 Nov 1;123(9):2020-30. doi: 10.1002/ijc.23735.

22.

Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis.

Nissen LJ, Cao R, Hedlund EM, Wang Z, Zhao X, Wetterskog D, Funa K, Bråkenhielm E, Cao Y.

J Clin Invest. 2007 Oct;117(10):2766-77.

23.

Loss of redness (a*) as a tool to follow hemoglobin-mediated lipid oxidation in washed cod mince.

Wetterskog D, Undeland I.

J Agric Food Chem. 2004 Dec 1;52(24):7214-21.

PMID:
15563197
24.

p73 competes with co-activators and recruits histone deacetylase to NF-Y in the repression of PDGF beta-receptor.

Uramoto H, Wetterskog D, Hackzell A, Matsumoto Y, Funa K.

J Cell Sci. 2004 Oct 15;117(Pt 22):5323-31. Epub 2004 Sep 28.

25.

pRb, Myc and p53 are critically involved in SV40 large T antigen repression of PDGF beta-receptor transcription.

Uramoto H, Hackzell A, Wetterskog D, Ballági A, Izumi H, Funa K.

J Cell Sci. 2004 Aug 1;117(Pt 17):3855-65. Epub 2004 Jul 20.

26.

Structure, organization and expression of the genes encoding mitochondrial cytochrome c(1) and the Rieske iron-sulfur protein in Chlamydomonas reinhardtii.

Atteia A, van Lis R, Wetterskog D, Gutiérrez-Cirlos EB, Ongay-Larios L, Franzén LG, González-Halphen D.

Mol Genet Genomics. 2003 Feb;268(5):637-44. Epub 2003 Jan 15.

PMID:
12589438
27.

A monoclonal antibody directed against a synthetic peptide reacts with a cell surface rabbit class I MHC molecule.

Le Guern A, Wetterskog D, Marche PN, Kindt TJ.

Mol Immunol. 1987 May;24(5):455-61.

PMID:
3657790
28.

A rabbit helper T cell clone reactive against group-specific streptococcal carbohydrate.

Jackson S, Folks TM, Wetterskog DL, Kindt TJ.

J Immunol. 1984 Sep;133(3):1553-7.

PMID:
6205087
29.

Cell surface glycoproteins of rabbit lymphocytes: characterization with monoclonal antibodies.

Wilkinson JM, Wetterskog DL, Sogn JA, Kindt TJ.

Mol Immunol. 1984 Jan;21(1):95-103.

PMID:
6200770

Supplemental Content

Loading ...
Support Center